These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36562382)

  • 1. Fluoropyrimidine‑induced cardiotoxicity in colorectal cancer patients: a prospective observational trial (CHECKPOINT).
    Lombardi P; Aimar G; Peraldo-Neia C; Bonzano A; Depetris I; Fenocchio E; Filippi R; Quarà V; Milanesio M; Cavalloni G; Gammaitoni L; Basiricò M; Cagnazzo C; Ostano P; Chiorino G; Aglietta M; Leone F
    Oncol Rep; 2023 Feb; 49(2):. PubMed ID: 36562382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and risk factors for capecitabine-induced symptomatic cardiotoxicity: a retrospective study of 452 consecutive patients with metastatic breast cancer.
    Polk A; Shahmarvand N; Vistisen K; Vaage-Nilsen M; Larsen FO; Schou M; Nielsen DL
    BMJ Open; 2016 Oct; 6(10):e012798. PubMed ID: 27798021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for fluoropyrimidine-induced cardiotoxicity in colorectal cancer: A retrospective cohort study and establishment of a prediction nomogram for 5-FU induced cardiotoxicity.
    Wang Y; Wang W; Dong H; Wang G; Chen W; Chen J; Chen W
    Front Oncol; 2023; 13():1017237. PubMed ID: 36937428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: A retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group.
    Kwakman JJ; Simkens LH; Mol L; Kok WE; Koopman M; Punt CJ
    Eur J Cancer; 2017 May; 76():93-99. PubMed ID: 28286287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and risk markers of 5-fluorouracil and capecitabine cardiotoxicity in patients with colorectal cancer.
    Dyhl-Polk A; Vaage-Nilsen M; Schou M; Vistisen KK; Lund CM; Kümler T; Appel JM; Nielsen DL
    Acta Oncol; 2020 Apr; 59(4):475-483. PubMed ID: 31931649
    [No Abstract]   [Full Text] [Related]  

  • 6. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study.
    Kosmas C; Kallistratos MS; Kopterides P; Syrios J; Skopelitis H; Mylonakis N; Karabelis A; Tsavaris N
    J Cancer Res Clin Oncol; 2008 Jan; 134(1):75-82. PubMed ID: 17636329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study.
    Peng J; Dong C; Wang C; Li W; Yu H; Zhang M; Zhao Q; Zhu B; Zhang J; Li W; Wang F; Wu Q; Zhou W; Yuan Y; Qiu M; Chen G
    Cancer Commun (Lond); 2018 May; 38(1):22. PubMed ID: 29764506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-existing chronic kidney disease and hypertension increased the risk of cardiotoxicity among colorectal cancer patients treated with anticancer drugs.
    Ho CC; Wen PC; Yu WC; Hu YW; Yang CC
    J Chin Med Assoc; 2021 Sep; 84(9):877-884. PubMed ID: 34320515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paradoxical effect of capecitabine in 5-fluorouracil-induced cardiotoxicity: A case vignette and literature review.
    Saneeymehri SS; Markey KR; Mahipal A
    J Oncol Pharm Pract; 2016 Jun; 22(3):552-5. PubMed ID: 25852107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of major adverse cardiac event in low risk chest pain patients in emergency department of Rajavithi Hospital.
    Piyanuttapull S; Ledarmonpat T
    J Med Assoc Thai; 2014 Nov; 97 Suppl 11():S111-6. PubMed ID: 25509704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vectorcardiography risk stratifies emergency department chest pain patients with left ventricular hypertrophy on the initial 12-lead ECG.
    Fesmire FM; Eriksson SV
    Ann Noninvasive Electrocardiol; 2004 Apr; 9(2):149-55. PubMed ID: 15084212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The puzzling clinical presentation of fluoropyrimidines cardiotoxicity.
    Cucciniello L; Bidoli E; Viel E; Canale ML; Gerratana L; Lestuzzi C
    Front Cardiovasc Med; 2022; 9():960240. PubMed ID: 36186986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using Machine Learning Approaches to Predict Short-Term Risk of Cardiotoxicity Among Patients with Colorectal Cancer After Starting Fluoropyrimidine-Based Chemotherapy.
    Li C; Chen L; Chou C; Ngorsuraches S; Qian J
    Cardiovasc Toxicol; 2022 Feb; 22(2):130-140. PubMed ID: 34792740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel outpatient regimen in management of fluoropyrimidine-induced cardiotoxicity.
    Kasi A; Gaudel P; Lekkala M; Al-Rajabi R; Saeed A; Sun W; Porter C
    J Oncol Pharm Pract; 2023 Dec; 29(8):1951-1956. PubMed ID: 36883259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EVALUATION OF 5-FLUOROURACIL-INDUCED CARDIOTOXICITY: ROLE OF CARDIAC BIOMARKERS.
    Moghaddam Z; Rostami M; Zeraatchi A; Abadi H; Karamitanha F; Amirmoghaddami H
    Exp Oncol; 2022 May; 44(1):60-66. PubMed ID: 35548958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of long-term symptom burden and quality of life in patients hospitalised with chest pain: a prospective observational study.
    Saeed N; Norekvål TM; Steiro OT; Tjora HL; Langørgen J; Bjørneklett RO; Skadberg Ø; Bonarjee VVS; Mjelva ØR; Omland T; Vikenes K; Aakre KM
    BMJ Open; 2022 Jul; 12(7):e062302. PubMed ID: 35831040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac biomarkers for the detection of cardiotoxicity in childhood cancer-a meta-analysis.
    Michel L; Mincu RI; Mrotzek SM; Korste S; Neudorf U; Rassaf T; Totzeck M
    ESC Heart Fail; 2020 Apr; 7(2):423-433. PubMed ID: 32069386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What is the incidence of major adverse cardiac events in emergency department chest pain patients with a normal ECG, thrombolysis in myocardial infarction score of zero and initial troponin <=99th centile: an observational study?
    Kelly AM
    Emerg Med J; 2013 Jan; 30(1):15-8. PubMed ID: 22328637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modern Management of Anthracycline-Induced Cardiotoxicity in Lymphoma Patients: Low Occurrence of Cardiotoxicity with Comprehensive Assessment and Tailored Substitution by Nonpegylated Liposomal Doxorubicin.
    Olivieri J; Perna GP; Bocci C; Montevecchi C; Olivieri A; Leoni P; Gini G
    Oncologist; 2017 Apr; 22(4):422-431. PubMed ID: 28275118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum biomarkers evaluation to predict chemotherapy-induced cardiotoxicity in breast cancer patients.
    De Iuliis F; Salerno G; Taglieri L; De Biase L; Lanza R; Cardelli P; Scarpa S
    Tumour Biol; 2016 Mar; 37(3):3379-87. PubMed ID: 26449821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.